Is CRISPR Therapeutics Really Headed to $110?
CRISPR Therapeutics (NASDAQ: CRSP), once a high flyer due to its cutting-edge, genome-editing solutions, is one of the more unpopular healthcare stocks this week.
That's almost entirely because of the death of one of the patients participating in an early-stage clinical trial for the company's T-cell cancer-treatment candidate, CTX110, which was reported along with the study's results on Wednesday.
Image source: Getty Images.
Source Fool.com
